Pancreatic Cancer Research

ResearcherJikei University School of MedicineActive in the last 2 years

Kyohei Abe

Matched on ORCID iD 0000-0001-8836-0112; OpenAlex author ID A5102832970. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 3 papers

Papers 10

  1. The preoperative cachexia index predicts outcomes after pancreatic resection for resectable pancreatic cancer. Co-author DOI 10.1007/s00595-025-03088-w↗
  2. Timing of TS1 adjuvant chemotherapy as a prognostic factor in recurrent pancreatic cancer after surgery. Co-author DOI 10.1016/j.suronc.2024.102179↗
  3. Prognostic Impact of a Decrease in Serum Carbohydrate Antigen 19-9 Levels After Preoperative Therapy for 4 Months or More for Borderline Resectable Pancreatic … Co-author DOI 10.1177/00031348241278016↗
  4. Effect of Risk Factor Score on Early Recurrence After Pancreatectomy for Invasive Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.16968↗
  5. Superior mesenteric vein/portal vein contact in preoperative imaging indicates biological malignancy in anatomically resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2023.101998↗
  6. The Impact of Fibrinogen to Prognostic Nutritional Index Rate on Prognosis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1177/00031348231204912↗
  7. D1 Distal Pancreatectomy for Left-sided Pancreatic Ductal Adenocarcinoma Is Justifiable: A Propensity-score Matched Multicenter Study. Co-author DOI 10.21873/anticanres.16150↗
  8. Effects of an enteral nutrient-rich therapy with omega-3 fatty acids in patients with unresectable or recurrent biliary tract cancer or pancreatic cancer durin… Co-author DOI 10.1007/s12032-021-01625-4↗
  9. Impact of osteopenia on surgical and oncological outcomes in patients with pancreatic cancer. Co-author DOI 10.1007/s10147-021-01986-w↗
  10. Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy. Co-author DOI 10.21873/anticanres.12485↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toru Ikegami · 9 shared papers, 2021–2025 · strength 1.68
  2. Ryoga Hamura · 8 shared papers, 2022–2025 · strength 1.54
  3. Kenei Furukawa · 8 shared papers, 2021–2025 · strength 1.52
  4. Koichiro Haruki · 8 shared papers, 2018–2025 · strength 1.44
  5. Yoshihiro Shirai · 8 shared papers, 2021–2025 · strength 1.43
  6. Masashi Tsunematsu · 7 shared papers, 2023–2025 · strength 1.39
  7. Shinji Onda · 7 shared papers, 2018–2025 · strength 1.22
  8. Michinori Matsumoto · 6 shared papers, 2021–2025 · strength 1.12
  9. Takeshi Gocho · 5 shared papers, 2018–2025 · strength 0.79
  10. Tadashi Uwagawa · 4 shared papers, 2018–2025 · strength 0.61
  11. Yoshiaki Tanji · 3 shared papers, 2023–2024 · strength 0.51
  12. Hironori Shiozaki · 3 shared papers, 2022–2024 · strength 0.50
  13. Shuichi Fujioka · 2 shared papers, 2023–2025 · strength 0.40
  14. Taro Sakamoto · 3 shared papers, 2018–2023 · strength 0.40
  15. Yosuke Igarashi · 2 shared papers, 2023–2025 · strength 0.39
  16. Mitsuru Yanagaki · 2 shared papers, 2023 · strength 0.32
  17. Tadashi Uwagawa · 1 shared paper, 2025 · strength 0.25
  18. Norimitsu Okui · 1 shared paper, 2025 · strength 0.22
  19. Tomohiko Taniai · 1 shared paper, 2023 · strength 0.15
  20. Katsuhiko K. Yanaga · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.